Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hutchison MediPharma Starts Clinical Trial of Second Cancer Drug

publication date: Feb 1, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, the drug discovery arm of Chi-Med, has begun a Phase I trial of its second anti-angiogenesis cancer drug candidate, fruquintinib. The first molecule, sulfatinib (HMPL-012), began clinical trials in April of 2010. According to Hutchison, fruquintinib showed “potent” anti-angiogenesis activity in pre-clinical testing. More details....

Stock Symbol: (AIM: HCM)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners